OPKO Health, Inc. (NASDAQ: OPK) is a leading healthcare company involved in diagnostics and pharmaceuticals. The company focuses on developing innovative treatments. As highlighted by GlobeNewswire, its subsidiary ModeX is advancing multispecific antibody programs for in vivo CAR T cell therapies, which aim to create cancer-fighting cells directly inside the body.
On July 27, 2026, OPKO Health announced its second-quarter earnings results. The company posts an earnings per share (EPS) of -$0.01. This figure is a significant improvement from the -$0.19 loss per share from the same quarter last year. It also beats the Zacks Consensus Estimate of -$0.08 by an impressive 87.5%.
The company also reports strong revenue performance for the quarter. OPKO Health's revenue of $163.5 million represents a 4.3% increase year-over-year. This result exceeds the consensus estimate of $131.23 million by 24.68%, as noted by Zacks. Over the last four quarters, the company has surpassed revenue estimates two times.
Looking at its valuation, OPKO Health has a negative Price-to-Earnings (P/E) ratio of -13.33. A negative P/E ratio means the company was not profitable over the last twelve months. The company’s Price-to-Sales ratio, which compares its stock price to its revenues, currently stands at 1.59.
The company's balance sheet shows a low Debt-to-Equity ratio of 0.12, indicating it has little debt compared to its equity. OPKO Health also maintains a current ratio of 3.35. A current ratio above one suggests a company has enough short-term assets to cover its short-term liabilities.
